|

JS004 Clinical Trials

2 actively recruiting trials

Also known as: tifcemalimab

Pipeline

Phase 2: 2

Top Sponsors

  • Shanghai Pulmonary Hospital, Shanghai, China1
  • Fudan University1

Indications

  • Cancer2
  • Clear Cell Renal Cell Carcinoma1
  • Limited Stage Small Cell Lung Cancer1
  • Lung Cancer1

Other2 trials

Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.